Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
Raffaele Ornello, Cindy Tiseo, Ilaria Frattale, et al.
The Journal of Headache and Pain (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Raffaele Ornello, Alfonsina Casalena, Ilaria Frattale, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 151
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
Antonio Russo, Marcello Silvestro, Fabrizio Scotto di Clemente, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 121
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
Armin Scheffler, Olga Messel, Sebastian Wurthmann, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 89
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Bianca Raffaelli, Rea Kalantzis, Jasper Mecklenburg, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 79
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, et al.
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 6, pp. 627-641
Closed Access | Times Cited: 60
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
Jamie Talbot, Rebecca Stuckey, Louise Crawford, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 43
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
Umberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
Neurological Sciences (2021) Vol. 43, Iss. 2, pp. 1273-1280
Closed Access | Times Cited: 41
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
Umberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
Cephalalgia (2022) Vol. 42, Iss. 7, pp. 645-653
Open Access | Times Cited: 29
Erenumab in Chronic Migraine: An Australian Experience
Shuli Cheng, Bronwyn Jenkins, Nicole Limberg, et al.
Headache The Journal of Head and Face Pain (2020) Vol. 60, Iss. 10, pp. 2555-2562
Closed Access | Times Cited: 45
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Raffaele Ornello, Alfonsina Casalena, Ilaria Frattale, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 41
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
R. Belvís, Pablo Irimia, Patricia Pozo‐Rosich, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 39
Clinic and genetic predictors in response to erenumab
Chiara Zecca, Sarah Cargnin, Christoph J. Schankin, et al.
European Journal of Neurology (2021) Vol. 29, Iss. 4, pp. 1209-1217
Open Access | Times Cited: 39
Real-world effectiveness of erenumab in Japanese patients with migraine
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e26568-e26568
Open Access | Times Cited: 5
Monoclonal Antibodies for Chronic Pain Treatment: Present and Future
Eva Sánchez-Robles, Rocı́o Girón, Nancy Paniagua, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10325-10325
Open Access | Times Cited: 29
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
Michael E. Lowe, Lesley Murray, Alok Tyagi, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 20
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
Laura Pilati, A de Torrenté, Salvatore Di Marco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3585-3585
Open Access | Times Cited: 11
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
Maria Michela Cainazzo, Carlo Baraldi, Anna Ferrari, et al.
Neurological Sciences (2021) Vol. 42, Iss. 10, pp. 4193-4202
Closed Access | Times Cited: 27
MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment
Raffaele Ornello, Veronica Zelli, Chiara Compagnoni, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
Raffaele Ornello, Ilaria Frattale, Valeria Caponnetto, et al.
Brain Sciences (2021) Vol. 11, Iss. 3, pp. 370-370
Open Access | Times Cited: 21
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
Andreas Straube, Philipp Stude, Charly Gaul, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Migraine and Sport in a Physically Active Population of Students: Results of a Cross‐Sectional Study
Laura Pilati, Giuseppe Battaglia, Vincenzo Di Stefano, et al.
Headache The Journal of Head and Face Pain (2020) Vol. 60, Iss. 10, pp. 2330-2339
Closed Access | Times Cited: 20
Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada
Marzieh Eghtesadi, Élizabeth Leroux, M. Gabrielle Pagé
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 733-739
Closed Access | Times Cited: 15
Erenumab efficacy in migraine headache prophylaxis: A systematic review
Mahsa Bagherzadeh-Fard, Mohammad Amin Yazdanifar, Mona Sadeghalvad, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109366-109366
Closed Access | Times Cited: 5
Anti-CGRP monoclonal antibodies improve cognitive function in patients affected by chronic migraine complicated with medication overuse-headache
Simona Guerzoni, Flavia Lo Castro, Carlo Baraldi, et al.
Confinia Cephalalgica (2024) Vol. 34, Iss. 1
Open Access | Times Cited: 1
Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
Yanbo Yang, Mingjia Chen, Da Wu, et al.
Current Neuropharmacology (2021) Vol. 20, Iss. 2, pp. 460-470
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top